Table 5.

Antibodies E1L3N and QR1 cell signaling; score according to histological subtype.

E1L3N antibody	CPS immunoscore				NR	TPS score (%)
	0	0-10	10-50	50-100		0	0-10	10-50	50-100
Serous carcinoma	77	16	6	1		81	15	3	1
High grade serous carcinoma	58	15	6	1	19	62	14	3	1
Low grade serous carcinoma	19	1			3	19	1
Endometrioid carcinoma	28	7				30	5
Grade G1	13	2			1	14	1
Grade G2	6	2			6	7	1
Grade G3	9	3			5	9	3
Clear cell carcinoma	16	3	2	1	5	16	3	2	1
Mucinous carcinoma	9				5	9
Seromucinous carcinoma	6	1			1	6	1
Carcinosarcoma	3	2			2	3	2
Malignant Brenner tumor	1					1
SCST or GCT	2					2
Granulosa	2				1	2
Immature teratoma					1
Embryonal carcinoma					1
Sertoli-Leydig tumor					1
Total	142	29	8	2	51	148	26	5	2
	61%	13%	3%	1%	22%	64%	11%	2%	1%
QR1 antibody	0	0-10	10-50	50-100	NR	0	0-10	10-50	50-100
Serous carcinoma	72	42	1	1		90	25		1
High grade serous carcinoma	55	37	1	1	5	71	22		1
Low grade serous carcinoma	17	5			1	19	3
Endometrioid carcinoma	35	9	1			39	6
Grade G1	13	2			1	14	1	4	0
Grade G2	14					14
Grade G3	8	7	1		1	11	5
Clear cell carcinoma	19	4	4	0		22	1
Mucinous carcinoma	11	1			2	11	1
Seromucinous carcinoma	8					8
Carcinosarcoma	5	0			2	5	0
Malignant Brenner Tumor	1					1
SCST ot GCT	4	2				5	1
Granulosa	2	1				2	1
Immature teratoma	1					1
Embryonar carcinoma	1					1
Sertoli-Leydig tumor		1				1
Total	155	58	6	1	12	181	34	4	1
	67%	25%	3%	0%	5%	78%	15%	2%	0%